(Q80288230)
Statements
Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy (English)
Stefanie Srock
Folke Schriever
Andreas Neubauer
Michael Herold